title: Effective treatment of chronically progressive multiple sclerosis with low-dose cyclophosphamide with minor side-effects.
abstract: Twenty-one multiple sclerosis (MS) patients with a chronically progressive course were treated with a low dose of cyclophosphamide (CY). The control group consisted of 21 MS patients with a chronically progressive course who received the standard treatment (ACTH or cortisone). The control group consisted of patients who preferred the standard therapy because of its beneficial effects. In contrast, the patients of the CY group wanted to try a new therapy because the standard therapy was not effective. Thus before starting the study the progression of the disease was faster in the CY group than in the standard therapy group. As regards age, sex and degree of disability, the two groups were comparable. For 20 of the 21 patients in the CY group the degree of disability (Kurtzke scale) remained stable over 1 year; for 2 of the 20 stable patients there was even an improvement. In the standard therapy group, 7 out of 21 patients were stable over 1 year, while 14 showed progressive disability. A quantitative neurological score at the beginning and 1 year after the therapy showed a nearly identical difference between the CY group and the control group. The changes of the patients' abilities in daily-life activities (which were observed and recorded by the nurses) were similar to the Kurtzke scale data obtained by the physicians. The beneficial effect of CY in chronically progressive MS was thus highly significant (P less than 0.001). The side-effects of low-dose CY were fewer than those of ACTH.
authors.affiliation: Department of Neurology, Ulm University, Dietenbronn, Federal Republic of Germany.
authors.forename: E
authors.initials: E
authors.lastname: Mauch
authors.forename: H H
authors.initials: HH
authors.lastname: Kornhuber
authors.forename: U
authors.initials: U
authors.lastname: Pfrommer
authors.forename: A
authors.initials: A
authors.lastname: Hähnel
authors.forename: H
authors.initials: H
authors.lastname: Laufen
authors.forename: H
authors.initials: H
authors.lastname: Krapf
mesh_terms: D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*
chemical_list: D003520:Cyclophosphamide